Clinical Trials on Advanced Haematological Malignancies in China

Total 1827 results

Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Available

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Relapsed and Refractory Hematological Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Relapsed/Refractory Hematological Malignancies

China
Shandong University
Juventas Cell Therapy Ltd.

Unknown

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Relapsed or Refractory Hematological Malignancies

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Peking University People's Hospital
Sanofi

Recruiting

The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation

Hematological Malignancy

China
RenJi Hospital

Recruiting

Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation

Haematological Malignancy

China
Shanxi Bethune Hospital

Recruiting

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Hematological Malignancy

China
Zhejiang University

Recruiting

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

Hematological Malignancy

China
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China
Zhongnan Hospital

Recruiting

CXCR4-targeted PET/CT Imaging in Hematological Malignancies

Hematological Malignancy | CXCR4 | PET/CT

China
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of IBI323 in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Advanced Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Advanced Malignancies

China
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

Phase I Clinical Study of BR105 Injection (BR105-I)

Advanced Malignancies

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL93 in Solid Tumors.

Advanced Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 in Patients With Advanced Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

Advanced Malignancies

China
Zhongnan Hospital

Recruiting

A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors

Hematological Malignancy | Cancer-Related Anemia

China
The Affiliated People's Hospital of Ningbo University

Recruiting

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Hematological Malignancy

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Advanced Malignancies

China
AstraZeneca

Completed

10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
AstraZeneca

Completed

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
BioRay Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

China
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

China
Beijing Immunochina Medical Science & Technology...

Unknown

Safety and Efficacy Evaluation of IM19 Cells

Hematological Malignancies

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Hematological Malignancies

China
Zhejiang University

Not yet recruiting

Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

Hematological Malignancies

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Advanced Or Metastatic Solid Tumor Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Novartis Pharmaceuticals

Completed

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Advanced Malignancies

Japan
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Recruiting

A Phase I Study of BR108 in Hematological Malignancies

Hematologic Malignancy

China
First Affiliated Hospital of Zhejiang University

Recruiting

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Leukemia

China
Children's Hospital of Fudan University

Recruiting

Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE)

Solid Tumor | Hematological Malignancies

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

Hematological Malignancies

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Advanced Malignancies

Japan
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Advanced Solid Tumors | Advanced Hematologic Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Advanced Malignancies | PD-1 Antibody | CAR-T Cells

China
Chinese PLA General Hospital

Recruiting

Ruxolitinib and Decitabine for High Risk Hematological Malignancies

Peripheral Blood Stem Cell Transplantation

China
Nanfang Hospital of Southern Medical University
The Seventh Affiliated Hospital of Sun Yat-sen University; The First People... and other collaborators

Recruiting

Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

Hematopoietic Stem Cell Transplantation | Hematological Malignancies

China
Chinese PLA General Hospital

Recruiting

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Solid Tumor | Hematological Malignancy

China
Ying Wang

Recruiting

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Hematological Malignancies

China

3

Subscribe